Update on anti-emetics for chemotherapy-induced emesisOLVER, I. N.Internal medicine journal (Print). 2005, Vol 35, Num 8, pp 478-481, issn 1444-0903, 4 p.Article

Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomitingOLVER, I. N.International journal of clinical practice (Esher). 2004, Vol 58, Num 2, pp 201-206, issn 1368-5031, 6 p.Article

A mass of exam nervesOLVER, I. N.Current therapeutics. 1999, Vol 40, Num 8, pp 44-46, issn 0311-905XArticle

Management of : Prostate cancerOLVER, I. N.Current therapeutics. 1999, Vol 40, Num 7, pp 73-81, issn 0311-905X, 6 p.Article

Antiemetic study methodology : Recommendations for future studiesOLVER, I. N.Oncology. 1996, Vol 53, pp 96-101, issn 0030-2414, SUP1Conference Paper

Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancerPHILLIPS, K. A; FRIEDLANDER, M; OLVER, I et al.Australian and New Zealand journal of medicine. 1995, Vol 25, Num 4, pp 337-343, issn 0004-8291Conference Paper

A multicentre, double-blind study comparing placebo, ondansetron and ordansetron plus dexamethasone for the control of cisplatin-induced delayed emesisOLVER, I; PASKA, W; DEPIERRE, A et al.Annals of oncology. 1996, Vol 7, Num 9, pp 945-952, issn 0923-7534Article

A phase II trial of zeniplatin in metastatic melanomaOLVER, I; GREEN, M; PETERS, W et al.American journal of clinical oncology. 1995, Vol 18, Num 1, pp 56-58, issn 0277-3732Article

Open label, multi-centre phase II study of raltitrexed ('Tomudex') in patients with inoperable squamous-cell carcinoma of head and neckCLARKE, S. J; ZALCBERG, J; OLVER, I et al.Annals of oncology. 2000, Vol 11, Num 2, pp 239-241, issn 0923-7534Article

Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cellsBASSER, R. L; TO, L. B; GILL, P. G et al.Clinical cancer research. 1995, Vol 1, Num 7, pp 715-721, issn 1078-0432Article

Radiation and carboplatin combined-modality therapy in non-small cell lung cancerBISHOP, J. F; BALL, D; CRENNAN, E et al.Seminars in oncology. 1994, Vol 21, Num 3, pp 91-96, issn 0093-7754, SUP6Conference Paper

Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancerOLVER, I; KEEFE, D; MYERS, M et al.Internal medicine journal (Print). 2005, Vol 35, Num 7, pp 405-408, issn 1444-0903, 4 p.Article

Rapid hematopoietic recovery after multicycle high-dose chemotherapy : Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factorBASSER, R. L; TO, L. B; COLLINS, J et al.Journal of clinical oncology. 1998, Vol 16, Num 5, pp 1899-1908, issn 0732-183XArticle

Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer : A randomised placebo-controlled trialBELLER, E; TATTERSALL, M; BOADLE, D et al.Annals of oncology. 1997, Vol 8, Num 3, pp 277-283, issn 0923-7534Article

Antiemetic studies: a methodological discussionOLVER, I. N; SIMON, R. M; AISNER, J et al.Cancer treatment reports. 1986, Vol 70, Num 5, pp 555-563, issn 0361-5960Article

Conflict of interests and advisory committeesTATTERSALL, M. H. N; OLVER, I. N.International journal of pharmaceutical medicine. 1999, Vol 13, Num 6, pp 325-328, issn 1364-9027Article

Methodology in anti-emetic trialsOLVER, I. N.Oncology. 1992, Vol 49, Num 4, pp 269-272, issn 0030-2414Conference Paper

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerKHAN, O. A; RANSON, M; MICHAEL, M et al.British journal of cancer. 2008, Vol 98, Num 10, pp 1614-1618, issn 0007-0920, 5 p.Article

Statistical considerations in the design, conduct and analyses of antiemetic clinical trials : An emerging consensusMORROW, G. R; BALLATORI, E; GROSHEN, S et al.Supportive care in cancer. 1998, Vol 6, Num 3, pp 261-265, issn 0941-4355Conference Paper

A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small-cell lung cancerBALL, D; SMITH, J; BISHOP, J et al.British journal of cancer. 1997, Vol 75, Num 5, pp 690-697, issn 0007-0920Article

A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer : Preliminary resultsBISHOP, J. F; DEWAR, J; LEVI, J et al.Seminars in oncology. 1997, Vol 24, Num 5, pp S17.5-S17.9, issn 0093-7754, SUP17Conference Paper

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceROILA, F; HERRSTEDT, J; GRUNBERG, S. M et al.Annals of oncology. 2010, Vol 21, issn 0923-7534, v232-v243, SUP5Article

Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphomaO'BRIEN, P; ROOS, D; PRATT, G et al.Journal of clinical oncology. 2000, Vol 18, Num 3, pp 519-526, issn 0732-183XArticle

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer : A report of the international CATAPULT I study groupVON PAWEL, J; VON ROEMELING, R; OLVER, I et al.Journal of clinical oncology. 2000, Vol 18, Num 6, pp 1351-1359, issn 0732-183XArticle

Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancerBISHOP, J; MURRAY, R; WEBSTER, L et al.Cancer chemotherapy and pharmacology. 1992, Vol 30, Num 3, pp 174-178, issn 0344-5704Article